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Background/aim: Hexarelin is a synthetic growth hormone-releasing peptide that exerts cardioprotective effects. However, its
cardioprotective effect against heart failure (HF) is yet to be explained. This study investigated the therapeutic role of hexarelin and the
mechanisms underlying its cardioprotective effects against coronary artery ligation (CAL)-induced HF in rats.
Materials and methods: Rats with four weeks of permanent CAL, induced myocardial infarction, and HF were randomly separated into
four groups: the control group (Ctrl), sham group (Sham), hexarelin treatment group (HF + Hx), and heart failure group (HF). The rats
were treated with subcutaneous injection of hexarelin (100 µg/kg) in the treatment group or saline in the other groups twice a day for
30 days. Left ventricular (LV) function, oxidative stress, apoptosis, molecular analyses, and cardiac structural and pathological changes
in rats were assessed.
Results: The treatment of HF rats with hexarelin signiﬁcantly induced the upregulation of phosphatase and tensin homologue (PTEN)
expression and inhibited the phosphorylation of protein kinase B (Akt) and mammalian target of rapamycin (mTOR) to significantly
improve LV function, ameliorate myocardial remodeling, and reduce oxidative stress.
Conclusion: These findings indicate that hexarelin attenuates CAL-induced HF in rats by ameliorating myocardial remodeling, LV
dysfunction, and oxidative stress via the upmodulation of PTEN signaling and downregulation of the Akt/mTOR signaling pathway.
Key words: PTEN, hexarelin, hypertrophy, infarction, heart, failure

1. Introduction
Globally, cardiovascular diseases have been identified as
the leading cause of morbidity and mortality with heart
failure (HF) being the main culprit over the past two
decades (1,2). After myocardial infarction, mimicked in
this study by the effect of coronary artery ligation (CAL), a
wide range of intrinsic pathological processes occur in the
myocardium causing myocardial remodeling and cardiac
dysfunction, which ultimately leads to HF and death (3–7).
However, in the present world, the treatment of myocardial
infarction and HF with pharmaceutical agents has not been
wholly successful and heart transplantation has not been a
feasible option due to the scarcity of organ donors (8). This
has therefore led to an increase in scientific research aimed
at elucidating mechanisms that underline the development
and regulation of cardiac remodeling and dysfunction
since they will be of extreme value in the prevention of
heart failure and other cardiovascular diseases.

Ghrelin, a known growth hormone secretagogue
secreted in the stomach, is an endogenous ligand of
GHSR1a with cardioprotective actions (9). Hexarelin is a
synthetic analog of ghrelin with similar cardioprotective
effects (10). Since it is much more chemically stable, it
has proved to be a promising alternative to ghrelin (10).
Numerous studies have reported on its beneficial actions
associated with the cardiovascular system including the
prevention of cardiomyocyte apoptosis (11), improved
cardiac output (12–14), antiatherosclerotic effects (15),
and cardiac fibrosis suppression (16). It binds to both
the growth hormone secretagogue receptor GHSR1a
and the cardiac non-GHSR receptor CD36 to exert its
cardioprotective effects (17).
In normal cellular functions, the PI3K/Akt/mTOR
pathway plays vital roles such as proliferation, migration,
adhesion, invasion, protein synthesis, energy metabolism,
autophagy, and prosurvival roles (18–20), and it has also
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been described as a classical cardioprotective pathway
(21).
Phosphatase and tensin homologue (PTEN) is a
lipid phosphatase responsible for the dephosphorylation
of phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)-P3] to produce PtdIns-(4,5)-P2, and therefore
plays the role of a PI3K/Akt antagonist (22) by negatively
regulating the PI3K/Akt/mTOR pathway.
The loss of PTEN in Drosophila has been demonstrated
to result in increased growth, whereas the overexpression
of PTEN has been shown to decrease cell size and cell
number (23). Moreover, in mouse cardiac muscle cells,
PTEN deletion has been demonstrated to result in
myocardial hypertrophy and is closely associated with the
upsurge in Akt activity and the size of individual myocytes
(24). These results are all consistent with the hypothesis
that the downregulation of PTEN results in increased Akt
activity and could lead to myocardial remodeling, which,
according to the literature, can ultimately lead to HF and
death. PTEN can therefore be a potential target in the
prevention of HF (25). However, whether the modulation
of PTEN signaling is involved in hexarelin-induced
cardioprotection is still unclear. Therefore, in the present
study, we investigated the therapeutic role of hexarelin and
the mechanisms underlying its cardioprotective effects
against HF by testing the hypothesis that hexarelin can
modulate PTEN to effectively attenuate CAL-induced HF
in rats.
2. Materials and methods
2.1. Animals
This study was approved by the animal research ethics
committee of Jiamusi University (No. 216-JMSU) and all
research procedures were strictly performed in conformity
with the guidance and suggestions for care and use of
laboratory animals, published by the Ministry of Science
and Technology of the People’s Republic of China. A total
of 96 male SD rats aged 10–12 weeks weighing between 210
g and 230 g were obtained from the Experimental Animal
Center of Harbin Medical University, Harbin, China. The
animals were maintained in a 22 ± 2 °C temperaturecontrolled room under a 12-h light/dark cycle and had free
access to food and water.
2.2. Drugs
Hexarelin (C47H58N12O6) was purchased from ProSpec
(East Brunswick, NJ, USA). In the experiments, hexarelin
was dissolved in saline to the desired concentration before
the administration of the drug.
2.3. Preparation of CAL-induced HF model and experimental protocols
First, 18 SD rats were randomly selected to form the control
group (Ctrl; n = 18), and the rest took part in the CAL
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surgical procedure. The HF model was induced via the
permanent ligation of the left anterior descending (LAD)
coronary artery as previously demonstrated (26). Briefly,
the SD rats were anesthetized by intraperitoneal (ip)
injection with 10% chloral hydrate (0.3 mL/100 g, ip) and
ventilated with a constant-volume rodent ventilator. After
left thoracotomy and pericardiotomy were performed,
the LAD coronary artery was permanently ligated using
a 7-0 silk suture at approximately 3 mm from its origin. A
confirmation of a successful CAL was done by the presence
of ST-segment elevation on an electrocardiogram (ECG)
and the presence of a color change at the ischemic region.
The heart was then positioned well in the intrathoracic
space, an evacuation of air was manually performed, and
then the muscles and skin were closed. Randomly selected
rats for the sham group (Sham; n = 18) underwent the
same surgical procedure except for ligation. Four weeks
after the surgery, the surviving ligated rats were divided
into the hexarelin treatment group (HF + Hx; n = 20) and
the heart failure group (HF; n = 20). All the rats in the four
groups were then treated for 30 days. HF + Hx rats were
treated with a subcutaneous injection of hexarelin (100 µg/
kg, sc, twice a day) (1), while the remaining groups were
treated with an equal volume of saline.
2.4. Echocardiography
Echocardiography was performed on all the rats after the
completion of the hexarelin and saline treatment. The SD
rats were first anesthetized by intraperitoneal injection
(ip) with 10% chloral hydrate (0.3 mL/100 g, ip) and an
experienced echocardiographer that had been blinded to
the 4 different groups of rat assignments recorded twodimensional M-mode stable images of the parasternal
long- and short-axis views using a Sonos 7500 (Philips)
echocardiographic system with the help of a 12-MHz
transducer. The following parameters were measured:
left ventricular end-diastolic diameter (LVEDD) and
left ventricular end-systolic diameter (LVESD), with left
ventricular ejection fraction (LVEF) being calculated in
real time. All the measurements were averaged from 3
consecutive cardiac cycles.
2.5. Tissue preparation
After the echocardiographic measurements were
performed, the hearts were rapidly harvested and tissues
from the noninfarcted regions of the left ventricles were
cut in cross-section at the papillary muscle level. Portions
of the samples were directly fixed in 10% phosphatebuffered formalin, dehydrated, and embedded in parafﬁn.
The other portions were frozen in liquid nitrogen, stored at
–80 °C, and later used for RT-qPCR and western blotting.
2.6. Heart hematoxylin and eosin (H&E) staining
The paraffin wax-embedded tissue samples were cut
into 4-µm slices. They were heated in a 60 °C incubator,
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dewaxed, and stained with H&E. A pathologist assessed
the sample slices from each group in a blinded fashion
and scored them for the following parameters: acute
myocardial necrosis or cell death, neutrophil inﬁltration,
degeneration of cardiac muscles, and hemorrhage.
2.7. Assessment of cardiac fibrosis with Masson’s trichrome staining
For the assessment of collagen fiber deposition as a marker
of cardiac fibrosis, 4-µm slices of paraffin wax-embedded
tissue samples that had been heated and dewaxed were
stained using Masson’s trichrome dye. An Olympus
DM4000 light microscope was used to capture the images
of the heart sections. The evaluation of the left ventricle
interstitial fibrosis area (LV interstitial fibrosis area =
collagen area in LV / total LV area) was done using ImagePro Plus 6.0 imaging software.
2.8. Assessment of cell apoptosis with Hoechst 33258
staining
Slices of paraffin wax-embedded tissue samples with
the size of 4 µm that had been dewaxed were stained
using Hoechst 33258 stain by strictly following the
manufacturer’s instructions. The slides were observed
using an Olympus fluorescence microscope and apoptosis
was measured using Image-Pro Plus 6.0.
2.9. Immunohistochemistry
Cardiac tissues were processed for immunohistochemistry
to analyze the expressions of PTEN, p-PTEN, Bax, Bcl-2,
and caspase-3 proteins. Briefly, 4-µm sections of formalinfixed, paraffin wax-embedded tissue samples were first
deparaffinized, rehydrated, and rinsed three times in
phosphate-buffered saline (PBS). Blocking of endogenous
peroxidase activity was achieved by incubation with 3%
hydrogen peroxide for 15 min at 37 °C and then washing
three times in PBS. The sections were incubated for 30 min
at 37 °C in goat serum to block nonspecific binding and
then washed three times in PBS. Incubation was performed
at 37 °C for 2 h with the following antibodies: antiBcl-2 (AF6139; 1:50) antibody purchased from Affinity
Biosciences (Cambridge, UK), anti-PTEN (ab31392;
1:500) and anti-p-PTEN (ab131107; 1:50) antibodies
purchased from Abcam (Cambridge, UK), and anti-Bax
(50599-2-Ig; 1:20) and Caspase-3 (19677-1-AP; 1:50)
antibodies purchased from Proteintech Group (Chicago,
IL, USA). After washing with PBS, the incubation of
the sections was done with biotinylated goat antirabbit
secondary antibody for 20 min and also with streptavidinhorseradish peroxidase (HRP) conjugated working
solution for 15 min at 37 °C before rinsing again with PBS.
The reaction was developed by 5 min of incubation with
3,3’-diaminobenzene (DAB) and counterstained for 30 s
with Mayer’s hematoxylin. After rinsing and dehydration,
the slides were mounted under a light microscope. Image-

Pro Plus 6.0 imaging software was used for the density
analysis of the images.
2.10. Measurement of cardiac superoxide dismutase
(SOD) and malondialdehyde (MDA) levels
Homogenates were prepared from the myocardial
tissues of the rats and the measurement of the levels of
SOD activity and MDA was performed using kits from
Nanjing Jiancheng Bioengineering Institute following the
manufacturer’s instructions.
2.11. Western blot analysis
Equal amounts of protein extracted from cardiac muscle
tissues with the use of a buffer were separated on SDSpolyacrylamide gels and were electrophoretically
transferred to polyvinylidene fluoride membranes. After
blocking the membranes with 5% nonfat milk, they were
incubated overnight at 4 °C with primary antibodies for
PTEN (ab31392; 1:500) and p-PTEN (ab131107; 1:500)
purchased from Abcam (Cambridge, UK), Akt (2920;
1:2000); p-Akt (4060S; 1:2000), mTOR (2983; 1:1000), and
p-mTOR (2971S; 1:1000) purchased from Cell Signaling
Technology (Danvers, MA, USA); GAPDH (1:1000)
purchased from Beyotime (Jiangsu, China); Bcl-2 (AF6139;
1:1000) and BNP (DF6902; 1:500) purchased from Affinity
Biosciences (Cambridge, UK); and Bax (50599-2-Ig;
1:1000) purchased from Proteintech Group (Chicago, IL,
USA). They were then incubated with HRP-conjugated
secondary antibody and the immunoreactive bands were
subsequently detected with a chemiluminescence kit.
2.12. Reverse-transcription quantitative real-time PCR
Total RNA was extracted from the myocardial tissues
using TRIzol reagent according to the manufacturer’s
instructions and was then reverse transcribed into
cDNA using the Takara Prime-Script RT reagent kit
(Takara, Dalian, China) according to the manufacturer’s
protocol. The primers used were synthesized by
Shanghai Sangon Biological Engineering Technology
and Services Co. (Shanghai, China) and are as follows:
BNP, forward: 5’-TGATTCTGCTCCTGCTTT-TC-3’,
reverse: 5’-GTGGATTGTTCTGGAGACTG-3’; β-MHC,
forward: 5’-ATG-CTGGCACCGTGGACT-3’, reverse:
5’-TTAGGAGCTTGAGGGAGGACTT-3’;
TGFβ1,
forward:
5’-AAGAAGTCACCCGCGTGCTA-3’,
reverse:
5’-TGTGT-GATGTCTTTGGTTTTGTCA-3’;
procollagen-I:
forward:
5’-TGCCGTGACCTCAAGATGTG-3’,
reverse:
5’-CACAAGCGTGCTGTAGGTGA-3’; and β-actin,
forward: 5’-GAGGCTCTCTTCCAGCCTTC-3’, reverse:
5’AGGGTGTAAAA-CGCAGCTCA-3’.
Reversetranscription quantitative real-time polymerase chain
reaction (RT-qPCR) for the quantiﬁcation of the gene
expressions was performed using Takara SYBR Premix
Ex Taq (Takara, Dalian, China). The expression of β-actin
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served as a control for the normalization of the expression
of genes of interest. The calculation of relative gene
expression was done using the 2–ΔΔCt method.
2.13. Statistical analysis
SPSS 24.0 for Windows (IBM Corp., Armonk, NY, USA)
was used for the statistical analysis. Experimental data
were expressed as mean ± standard deviation (SD). Oneway analysis of variance (ANOVA) or Welch’s method
followed by the LSD post hoc test when appropriate was
used to assess the statistical significance of the differences
between the various groups. P < 0.05 was considered to be
statistically signiﬁcant.
3. Results
3.1. Hexarelin improved LV function in CAL-induced
HF rats
As shown in Figures 1a and 1b, LVEDD and LVESD in the
HF group significantly increased (P < 0.05) compared with
the Ctrl group, indicating the enlargement of the heart
and the impairment of diastolic and systolic functions.
HF + Hx rats showed significantly decreased LVEDD and
LVESD (P < 0.05) compared with the HF rats, suggesting
that hexarelin ameliorates myocardial remodeling in
CAL-induced HF rats. Figure 1c shows that there was a

significant difference in LVEF between the HF group and
Ctrl group (P < 0.05). The LVEF of the HF group was
significantly lower than that of the Ctrl group. The LVEF of
the HF + Hx group was significantly increased (P < 0.05)
as compared to the HF group, which proves that hexarelin
could improve the cardiac contractile function in CALinduced HF rats.
3.2. The effects of hexarelin on the levels of SOD activity
and MDA content
Compared to the Ctrl group, there was a significant
increase (P < 0.05) in the MDA content (Figure 1d)
accompanied by a significant drop (P < 0.05) in the level of
SOD (Figure 1e) activity in the myocardium of HF group
rats. The administration of hexarelin markedly reversed
the decrease in the activity of SOD and the increase in
MDA levels induced by CAL (P < 0.05). These results
suggest that hexarelin exerts cardioprotective effects by
playing an antioxidant role.
3.3. Hexarelin ameliorated cardiac structural and pathological changes in CAL-induced HF rats
Figure 2a shows the images of H&E-stained cardiac
sections. Cardiac tissues in the HF group showed increased
myocardial and morphological damages compared with
rats in the Ctrl and Sham groups. These damages were

Figure 1. Echocardiographic results (a, b, c) showing the effects of hexarelin on CAL-induced HF rats with respect to: (a) LVEDD, (b)
LVESD, (c) LVEF. Protective effects of hexarelin on CAL-induced HF rats against oxidative stress with respect to (d) malondialdehyde
(MDA) and (e) superoxide dismutase (SOD). All data expressed as mean ± SD (n = 6). **P < 0.05.
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characterized by myocardial cell loss and structural
damage, loss of cross striations of myocardial fibers,
myocardium fragmentation, rupturing, and inﬁltration of
inﬂammatory cells (Figure 2a). The treatment of HF rats
with hexarelin (HF + Hx group) conspicuously ameliorated
the histopathological damages and pathophysiological
changes in the myocardium of the HF + Hx rats.
3.4. Hexarelin attenuated collagen deposition and myocardial ﬁbrosis in CAL-induced HF rats
Figure 2b shows representative photomicrographs of
Masson’s trichrome staining of noninfarcted left ventricular
tissues. Red color indicates normal tissues while blue color
indicates collagen fibers. The results of the present study
show that there was a markedly significant (P < 0.05)
increase in collagen deposition in the HF group compared
with the Ctrl group. However, the treatment of HF rats
with hexarelin (HF + Hx group) significantly attenuated
(P < 0.05) the level of fibrosis or deposition of collagen
although the difference between the HF + Hx group and
the Ctrl group was still significant. We further calculated
the LV interstitial fibrosis area in the cardiac tissues in
order to accurately compare the differences in interstitial

fibrosis level as well as cell survival among the groups. As
shown in Figure 2c, the percentage of the LV interstitial
fibrosis area was significantly elevated (P < 0.05) in the
HF group compared to the Ctrl group. However, the HF
+ Hx group showed a significant decrease (P < 0.05) in
the LV interstitial fibrosis area when compared to the HF
group. These results clearly show that hexarelin attenuates
collagen deposition and myocardial ﬁbrosis in CALinduced HF rats.
3.5. The effects of hexarelin on fibrosis and cardiac hypertrophic remodeling-related biomarkers
Quantitative real-time PCR analysis revealed that the
amounts of mRNA encoding transforming growth
factor-β1 (TGF-β1) and procollagen-I were significantly
increased (P < 0.05) in the HF group compared with the Ctrl
group (Figures 2d and 2e). Upregulation in the expression
of these genes was significantly inhibited (P < 0.05) in the
HF + Hx group when compared to the HF group. Western
blot analyses of the brain natriuretic peptide (BNP)
(Figure 3a) as well as the mRNA expressions of BNP
(Figure 3b) and β-myosin heavy chain (β-MHC) (Figure
3c) were all significantly elevated (P < 0.05) in the HF

Figure 2. (a) Representative images of H&E staining of left ventricular sections (200×). (b) Representative images of Masson’s trichrome
staining of left ventricular sections (200×). (c) Quantitation of left ventricular interstitial fibrosis area. (d, e) RT-qPCR analyses of
TGF-β1 and procollagen-I. All data expressed as mean ± SD (n = 6). **P < 0.05.
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group as compared to the Ctrl group. Hexarelin therapy, as
seen in the HF + Hx group, tended to significantly reduce
(P < 0.05) all these vital cardiac hypertrophic remodeling
parameters when compared to the HF group. These results
in total suggest that hexarelin ameliorates myocardial
remodeling-related cardiac hypertrophy and cardiac
fibrosis in CAL-induced HF rats.
3.6. The effects of hexarelin on apoptosis
Our western blot results (Figure 3d) revealed that
antiapoptotic protein Bcl-2 was significantly more highly
expressed in the Ctrl group than in the HF group rats (P
< 0.05) while the HF + Hx group showed a significantly
increased expression of Bcl-2 (P < 0.05) when compared to
the HF group.
The protein expression pattern of proapoptotic Bax was
in sharp contrast with the Bcl-2 results. Bax (Figure 3e) was
significantly highly expressed (P < 0.05) in the HF group
rats as compared to the Ctrl group, indicating a severe
increase in apoptosis during CAL-induced HF. However,
the treatment of the HF rats with hexarelin significantly
reduced (P < 0.05) the expression of Bax as seen when the
HF + Hx group was compared to the HF group.
The immunohistochemical expression patterns
of Bcl-2 and Bax (Figures 4a and 4b) were consistent
with the western blot expression patterns of Bcl-2 and

Bax proteins. Our immunohistochemistry results also
showed that, compared to the Ctrl group, the HF group
rats showed a significant increase (P < 0.05) in caspase-3
protein expression while the expression of caspase-3
(Figure 4c) was significantly decreased (P < 0.05) in the
HF + Hx group compared to the HF group. Moreover, the
quantitation of relative integral optical density values in
our immunohistochemistry results (Figures 4d–4f) were
all consistent with the immunohistochemical expression
patterns of Bcl-2, Bax, and caspase-3 described above. In
addition, Hoechst 33258 staining results (Figures 5a and
5b) revealed that the cardiomyocyte population showing
apoptotic and condensed nuclei was significantly higher
in the HF group compared to the Ctrl group, but was
significantly reduced when the HF rats were treated with
hexarelin (HF + Hx group). All these demonstrate that
hexarelin attenuates apoptosis in CAL-induced HF rats.
3.7. The effects of hexarelin in the modulation of PTEN in
CAL-induced HF rats
Western blot and immunohistochemical analysis of PTEN
were performed on cardiac tissue samples of rats in order
to identify the mechanisms underlying the therapeutic
role of hexarelin in attenuating CAL-induced myocardial
remodeling and HF in rats. Active forms of PTEN are
nonphosphorylated (PTEN) while inactive forms of PTEN

Figure 3. (a) Representative western blots and quantitation results of BNP. (b, c) RT-qPCR analyses of BNP and β-MHC. (d, e)
Representative western blots and quantitation results of Bcl-2 and Bax. All data expressed as mean ± SD (n = 6). **P < 0.05.
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are phosphorylated (p-PTEN). Compared to the Ctrl
group, our immunohistochemistry and western blot results
showed a significant decrease (P < 0.05) in the level of PTEN
protein expression (Figures 6a–6d) with a corresponding
significant increase (P < 0.05) in the p-PTEN protein
expression in the HF group (Figures 6e–6h). Interestingly,
the treatment of the HF rats with hexarelin (HF + Hx
group) revealed a significant increase (P < 0.05) in PTEN
with a corresponding significant decrease (P < 0.05) in the
protein expression level of p-PTEN in the HF + Hx group
when compared to the HF group. These results demonstrate
that hexarelin upregulates PTEN activation by increasing
the expression of PTEN with a corresponding decrease in
the level of p-PTEN to attenuate CAL-induced myocardial
remodeling and HF in rats.
3.8. The effects of hexarelin in the modulation of Akt/
mTOR pathway-related proteins in CAL-induced HF rats
After the upregulation of the active form of PTEN by
hexarelin, we further sought to investigate how hexarelin

modulates the known downstream PI3K/PTEN-pathway
components (Akt, p-Akt, mTOR, and p-mTOR) in CALinduced HF rats. As demonstrated by western blotting
(Figures 7a and 7b), the phosphorylation of Akt in the HF
group was significantly enhanced (P < 0.05) as compared to
the Ctrl group. However, compared to the HF group, there
was a significantly marked decrease in Akt phosphorylation
in the HF + Hx group due to the treatment of HF rats with
hexarelin. We also examined the protein content of mTOR,
a downstream target of Akt, by western blotting (Figures
7c and 7d). Expectedly, compared to the Ctrl group, our
results showed a significant increase in the expression level
of mTOR phosphorylation in the HF group. Interestingly,
the increase in mTOR phosphorylation level in the HF
group was reversed by the treatment of CAL-induced
HF rats with hexarelin (HF + Hx group). These results
show that hexarelin downregulates the phosphorylation
of Akt and mTOR to attenuate CAL-induced myocardial
remodeling and HF in rats.

Figure 4. (a, b, c) Immunohistochemical expressions of Bcl-2, Bax, and caspase-3 in left ventricular sections (200×). (d, e, f) Quantitation
of relative integral optical density (IOD) values of Bcl-2, Bax, and caspase-3. All data expressed as mean ± SD (n = 6). **P < 0.05.
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4. Discussion
The main ﬁnding of this study is that the administration
of hexarelin attenuates CAL-induced HF. Furthermore,
we demonstrated for the first time that the mechanism of
attenuation of HF by hexarelin is related to the upregulation
of PTEN signaling and downregulation of the Akt/mTOR
pathway. Our study also revealed that these beneﬁcial
effects of hexarelin were due to its capacity to reduce
oxidative stress as reﬂected by the increase in the activity
of SOD and the decrease in MDA levels, the inhibition
of apoptosis indicated by the decrease in the expression
of proapoptotic protein (Bax) and apoptotic effector
caspase-3 with a corresponding increase in antiapoptotic

protein (Bcl-2) expression, and the attenuation of cardiac
fibrosis and hypertrophic remodeling-related biomarkers
in the myocardium of CAL-induced HF rats.
After myocardial infarction, a wide range of intrinsic
pathological processes occur in the myocardium causing
myocardial remodeling and cardiac dysfunction, which
ultimately leads to HF and death (3–7). The present study
used the CAL procedure, which is a classical operation
method that is used to induce myocardial infarction
in rats (27,28) and has been proven and accepted to be
appropriate for the investigation of the pathophysiology of
myocardial infarction and myocardial remodeling as well
as HF in some rodents like mice and rats (26).

Figure 5. (a) Representative images of left ventricular sections showing the effect of hexarelin on apoptosis by Hoechst staining (200×).
(b) Relative apoptotic index. All data expressed as mean ± SD (n = 6). **P < 0.05.

952

AGBO et al. / Turk J Med Sci
Ventricular remodeling after a myocardial infarction is
mainly characterized in the initial stages by cardiomyocyte
death and an increase in inﬂammation in the periinfarcted
and infarcted zones of heart. This is then subsequently
followed by marked hypertrophy and fibrosis as well as the
accumulation of prominent extracellular matrix (ECM)
in the noninfarcted cardiac tissues in the later stages (29).
Cardiac ﬁbrosis is a consequence of an imbalance between
the processes in which ECM proteins are synthesized and

degraded and is considered as a key process involved in the
pathophysiology of heart failure (30). Collagen is a wellknown fibrous protein and a major component of the ECM
in heart. It is produced by fibroblasts. Moreover, its excessive
deposition, which is known as pathological ﬁbrosis, is a
major contributor to LV dysfunction and resulting HF
(31–33). Our study demonstrated that hexarelin treatment
markedly reduced the percentage of LV interstitial fibrosis
area, indicating the antifibrotic ability of hexarelin, which

Figure 6. (a, b) Immunohistochemical expressions and quantitation of relative integral optical density (IOD) values of PTEN (200×). (c,
d) Representative western blots and quantitation results of PTEN. (e, f) Immunohistochemical expressions and quantitation of relative
IOD values of p-PTEN (200×). (g, h) Representative western blots and quantitation results of p-PTEN. All data expressed as mean ± SD
(n = 6). *P < 0.05 with respect to HF versus Ctrl, #P < 0.05 with respect to HF + Hx versus HF.

953

AGBO et al. / Turk J Med Sci
in effect resulted in the improvement of cardiac contractile
function showed by echocardiographic results. In addition,
the mRNA expression level of procollagen-I, a biomarker
of fibrosis that reflects the intensity of myocardial collagen
synthesis (34–37), was significantly reduced by hexarelin
treatment. TGF-β1, which belongs to the TGF-β family
of proteins, is involved in the promotion of fibrosis in
cardiovascular and renal tissues by increasing the production
of ECM (38); hence, it is regarded as one of the molecular
indices that regulate myocardial ﬁbrosis. As speculated,
TGF-β1 mRNA expression level was also inhibited by
the hexarelin treatment of HF rats. Cardiac hypertrophy
has over the years been a potential target of anticardiac
remodeling therapy and several pieces of evidence in
humans are consistent with therapeutic targeting of the
myocardial hypertrophic process (39). Although shortterm cardiac hypertrophic remodeling is beneficial, its longterm activation is detrimental and pathological, leading to
a progression towards HF. Therefore, these strongly suggest
that the suppression of pathological cardiac hypertrophic
remodeling may be vital in impeding its progression
to HF (40). The characteristic pattern of protein and
mRNA expressions classically related to pathological LV
hypertrophy or remodeling involves increased BNP and
β-MHC levels. Consistent with our results in this study,
hexarelin markedly counteracted this characteristic pattern
of pathological LV remodeling. All these results in totality
strongly suggest that hexarelin ameliorates myocardial
remodeling-related cardiac hypertrophy and cardiac fibrosis
to improve cardiac contractile function in CAL-induced HF
rats and in effect attenuates HF.

Oxidative stress is one of the mechanisms underlying
myocardial damage (41). An increase in free oxygen
radicals produced in the ventricles after MI results in
lipid peroxidation that can indirectly be reflected through
ventricular MDA level. In our study, we observed that the
administration of hexarelin reversed the adverse increase
in MDA levels and also raised the level of endogenous
antioxidant SOD activity, which indicates strongly that
the antiperoxidative capacity of hexarelin partakes in the
protection of the heart to attenuate CAL-induced HF in
rats.
Some previous studies reported that hexarelin could
improve cardiac function (42) but the majority of them
failed to elucidate the mechanism by which hexarelin
exerts these cardioprotective functions. Therefore, our
study sought to bridge this mechanism research gap. There
has been accumulating evidence in several recent studies
suggesting a cardioprotective role involving the PTEN
gene (23,24,43–45). For example, an investigation on the
cardioprotective effects of simvastatin on the expression
of PTEN and the Akt signaling pathway revealed that
simvastatin reverses cardiomyocyte hypertrophy, which is
a characteristic feature of myocardial remodeling both in
vitro and in vivo via the upregulation of PTEN expression
and the downregulation of Akt (43). These results
therefore improve the prognosis of HF. Roy et al. used a
murine myocardial infarction model to demonstrate that
miR-21 modulates ﬁbroblast metalloprotease-2 through
PTEN (45). In their experiment, they showed that there
was a significant decrease in PTEN expressions in the
myocardial infarct zone of the heart as compared to that

Figure 7. (a, b, c, d) Representative western blots and quantitation results of Akt, p-Akt, mTOR, and p-mTOR. All data expressed as
mean ± SD (n = 6). **P < 0.05.
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of the control. This suggested that an upregulation of
PTEN could be beneficial and cardioprotective. Fu et al.
also showed that attenuation of microRNA-495 activates
PTEN to effectively protect cardiomyocytes of rats from
pathological cardiac hypertrophy or remodeling (44),
which will ultimately lead to an approach in the attenuation
of HF occurrence. Interestingly, our western blot and
immunohistochemical analyses in the present study
demonstrated that hexarelin upregulates PTEN activation
by increasing the expression of PTEN with a corresponding
decrease in the level of PTEN phosphorylation to attenuate
CAL-induced myocardial remodeling and heart failure in
rats, which strongly indicates that PTEN is associated with
the cardioprotective effect of hexarelin.
Although our results were consistent with the vast
majority of evidence supporting the protective role of
PTEN in heart failure, a study conducted by Oudit et al. in
2008 showed that the loss or inhibition of PTEN may help
to prevent ventricular hypertrophy (46). This discrepancy
can be explained by the existence of different experimental
models or protocols. In other words, PTEN might be
modulated differently depending on the cause of the
resulting heart failure. For instance, as demonstrated by the
current study, the upmodulation of PTEN signaling was
beneficial in the attenuation of CAL-induced ventricular
hypertrophy and HF, but the loss of PTEN prevented
ventricular hypertrophy in response to the pressure
overload by aortic banding in the experiment conducted
by Oudit et al. (46). This therefore implies that while the
activation of PTEN attenuates myocardial remodeling and
HF in the setting of myocardial infarction, the inhibition
of PTEN may ameliorate myocardial remodeling in the
setting of pressure overload such as hypertension.
Reactive oxygen species, known to cause oxidative
stress, are among the mechanisms underlying myocardial
damage (41) and were previously demonstrated to cause
the oxidation of PTEN, leading to the activation of the
PI3K/Akt pathway (47). Therefore, the loss of PTEN
activity in this rat HF model could result from reactive
oxygen-mediated degradation of PTEN. Since hexarelin
treatment decreased oxidative stress in the current study,
the antioxidant capacity of hexarelin could be responsible
for the increase in PTEN expression indirectly.
We further sought to investigate how hexarelin
modulates the known downstream PI3K/Akt-pathway
components since its role in cardiac hypertrophic
remodeling is well established. Cardiac hypertrophic
remodeling response after the activation of PI3K is
related to PI3K downstream Akt (48), a known serine/
threonine kinase associated with the regulation of
different cellular functions for cell survival like protein
synthesis, metabolism, proliferation, and glucose uptake.
The targeted overexpression of phosphorylated Akt in
the heart leads to cardiac hypertrophic remodeling (49)

by inhibiting GSK3β to induce cell protein synthetic
machinery (50). mTOR is a known serine–threonine
protein kinase that becomes activated through the
phosphorylation of TSC2 by Akt. The phosphorylation
of mTOR is involved in protein synthesis (51,52) and
results in cardiac hypertrophic remodeling (53) while the
pharmacological inhibition of mTOR is known to reverse
cardiac hypertrophic remodeling (54,55). The findings of
this study showed that treatment with hexarelin inhibited
the phosphorylation of Akt and mTOR accompanying
the attenuation of CAL-induced myocardial hypertrophic
remodeling and HF. Crackower et al. used mouse cardiac
muscle cells to demonstrate that PTEN deletion results
in myocardial hypertrophic remodeling and is closely
associated with the upsurge in Akt activity (24), suggesting
that PTEN activation inhibits Akt and thereby prevents
myocardial hypertrophic remodeling. Our results are
therefore consistent with their findings.
Several studies have emphasized that apoptosis is
associated with myocardial infarction (56–58) and the
progression to HF. The expressions of proapoptotic factors
like Bax and caspase-3 and an antiapoptotic factor like
Bcl-2 are associated with apoptosis (59). We found in our
study that hexarelin treatment reduced the expression of
proapoptotic factors like Bax and caspase-3 and increased
the expression of antiapoptotic Bcl-2, which all seemed
to support our Hoechst 33258 and H&E staining results
with regard to myocardial cell loss or apoptosis. Another
interesting observation in our study is that, although to
the best of our knowledge there are no reports on the
antiapoptotic action of hexarelin with regard to the Akt/
mTOR pathway, the inhibition of apoptosis by hexarelin
in our study was accompanied by the downregulation of
Akt activation, which seems to be contrary to most of the
literature (60). Our findings therefore raise the possibility
of the existence of Akt-independent antiapoptotic
signal induction by hexarelin, consistent with other
Akt-independent antiapoptotic actions by other agents
reported in some publications (61,62) and meriting further
investigations.
In conclusion, our findings revealed that hexarelin
attenuates CAL-induced HF in rats by ameliorating
myocardial remodeling, LV dysfunction, and oxidative
stress via the upmodulation of PTEN signaling and the
downregulation of the Akt/mTOR signaling pathway. Our
data provide insights into the mechanisms underlining
the possible application of hexarelin in patients with
myocardial infarction and HF.
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